Promising Evidence for use of Another Biologic for the Treatment of Uncontrolled Moderate to Severe Asthma

Posted on: 12 July, 2018

treatment-asthma

A study recently published in the New England Journal of Medicine suggests that the biologic, dupilumab, was effective in treating uncontrolled moderate to severe asthma.

Dupilumab is a biologic, or antibody therapy that acts to block a specific mechanism to decrease allergic inflammation. In this study of 1902 patients, patients on the medication had a decrease rate of asthma exacerbation as well as improvement in their breathing test scores.

Currently, dupilumab is only FDA approved for moderate to severe eczema which is another allergic condition. The FDA is in the process of reviewing dupilumab for use for asthma. For more information on the article, click the link: www.nejm.org/doi/full/10.1056/NEJMoa1804092

Make sure to follow and like us on social media including facebook, twitter and instagram to get the latest breaking news in allergy and immunology.

Conditions Treated

Allergy Shots

Allergy immunotherapy, also called “allergy shots,” is prescribed to modify the immune system’s response to allergens with the goal of minimizing and/or preventing an allergen initiated inflammatory response.
Allergy Drops & Tablets

Allergy drops, and tablets are two forms of sublingual immunotherapy that are injection-free alternatives to allergy shots. Both contain environmental allergen such as pollen, dust mites, molds, cat, or dog.
Asthma

Asthma is a chronic inflammatory lung condition that usually starts in childhood but can occur at any age. Allergists are considered the experts in asthma and diagnose this condition by history, exam and breathing tests of the airways.
Allergy & Sinus

Allergic rhinitis is one of the most common chronic conditions in the US. Individuals with allergic rhinitis develop allergy antibodies (IgE) targeted against allergens including pollen, animal proteins, dust mites, mold, and insect droppings.
Food Allergy

Food allergy affects 5% of children and 4% of adults in the United States and is defined as an adverse health event that is immune mediated and occurs reproducibly. Individuals with IgE mediated food allergy develop allergy antibodies (IgE) targeted against food allergens.
Allergic Rashes

Atopic dermatitis is a chronic, relapsing inflammatory skin disorder that usually starts at age < 5 years. It is characterized by itchy skin that becomes inflamed with scratching. For this reason, atopic dermatitis is known as the “itch that rashes.”
Other Conditions